US EditionBristol Myers Squibb to present positive new data on lymphoma treatment - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Bristol Myers Squibb to present positive new data on lymphoma treatment - Pharmafile
Bristol Myers Squibb (BMS) has announced positive results from the TRANSCEND FL phase 2 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory marginal zone lymphoma (MZL). The new data will be presented at the International Conference on Malignant Lymphoma, Lugano, Switzerland, on 19 June, building on data announced in February. Breyanzi […] The post Bristol Myers Squibb to present positive new da…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
